Zurich Insurance Group Ltd FI Has $16.94 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Zurich Insurance Group Ltd FI lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 62.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,784 shares of the biopharmaceutical company's stock after selling 39,857 shares during the period. Zurich Insurance Group Ltd FI's holdings in Regeneron Pharmaceuticals were worth $16,942,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. OLD Second National Bank of Aurora raised its stake in shares of Regeneron Pharmaceuticals by 0.5% in the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after purchasing an additional 15 shares in the last quarter. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares during the period. TD Private Client Wealth LLC raised its stake in Regeneron Pharmaceuticals by 9.6% during the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after acquiring an additional 15 shares during the period. Manchester Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 12.6% during the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock worth $115,000 after acquiring an additional 18 shares during the period. Finally, Financial Perspectives Inc raised its stake in Regeneron Pharmaceuticals by 10.9% during the fourth quarter. Financial Perspectives Inc now owns 193 shares of the biopharmaceutical company's stock worth $137,000 after acquiring an additional 19 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Analysts Set New Price Targets

REGN has been the subject of several recent analyst reports. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Citigroup upgraded shares of Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price objective for the company from $600.00 to $700.00 in a report on Wednesday, May 14th. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. Royal Bank of Canada decreased their price objective on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $890.60.

Regeneron Pharmaceuticals Trading Down 1.4%

Shares of NASDAQ:REGN traded down $8.51 during mid-day trading on Friday, hitting $588.34. The stock had a trading volume of 655,734 shares, compared to its average volume of 799,208. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market cap of $63.52 billion, a PE ratio of 15.37, a P/E/G ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 12-month low of $520.50 and a 12-month high of $1,211.20. The company's 50 day moving average is $592.38 and its 200-day moving average is $675.94.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company's quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the business earned $9.55 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.60%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.